# Phase II Study of Immunization With a Hepatitis C Virus (HCV) Antigen Peptide Vaccine

> **NCT00602784** · PHASE2 · COMPLETED · sponsor: **Valneva Austria GmbH** · enrollment: 66 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **BIOLOGICAL:** IC41

## Key facts

- **NCT ID:** NCT00602784
- **Lead sponsor:** Valneva Austria GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** 2004-05
- **Final completion:** 2004-09
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2012-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00602784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00602784, "Phase II Study of Immunization With a Hepatitis C Virus (HCV) Antigen Peptide Vaccine". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00602784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*